PennyStocksUpdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 03/06/2013 -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) shares boosted after declared that its new next generation pseudoephedrine with misuse deterrent technology will now be kept by chain drug store KERR DRUG. Nexafedis a 30 mg immediate-release pseudoephedrine product that combines operative nasal-congestion reprieve with an exclusive technology that interrupts the alteration of pseudoephedrine into the dangerous drug, methamphetamine (meth).
In the midday, Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) surged +58.05% to $3.24 and its total traded volume were 5.78 million shares.
What was the Moving Force behind ACUR On Bullish Run? Read This Research Report on ACUR
MGIC (NYSE:MTG) is selling 135 million common shares and $350 million in convertible notes. At Tuesday's closing price of $5.34 a share, the stock sale would generate almost $721 million. Additional grants to underwriters would put the total amount raised around $1.2 billion.
Last week, MGIC reported that its risk-to-capital ratio - one measure some regulators use in deciding whether an insurer can continue writing new policies - grew to 44.7-to-1 in the quarter. The most common acceptable ratio is 25-to-1.
The company said it expects the risk-to-capital ratio to go higher, but that it was considering taking measures to increase capital and improve the ratio. The prospect of raising capital has helped boost MGIC's stock price over the past few trading days.An MGIC competitor, Radian Group Inc., recently raised $689 million by selling stock and debt.
Should Investor Buy OR Sell This Stock : CLICK HERE
Cree Inc. ( NASDAQ:CREE) raised its adjusted earnings guidance for the third quarter Tuesday morning to a range of $0.31 to $0.36 per share from the prior forecast in the $0.30 to $0.35 per share range. The company also raised its third-quarter revenue guidance to a range of $335 million to $350 million from the prior estimate between $325 million and $345 million. The consensus estimates are for EPS of $0.33 and revenues of $336.06 million.
Cree gapped open sharply higher Tuesday and is now up 4.62 at $49.34 on above average volume. The stock has broken out of a 1-month trading range and has set a new high for the year.
How Should Investors React To CREE Now? Check here
InterOil Corporation (USA) (NYSE:IOC) went up 3.05% and closed at $68.56 on a traded volume of 1.07 million shares. InterOil Corporation announced that its advisors have informed the Company that several bids to partner with InterOil in its Gulf LNG project have been received. The advisors are now evaluating the submissions. The InterOil Board of Directors will meet the Company’s advisors during March 2013 for the purpose of evaluating bids received for the development of the Gulf LNG Project utilising gas from the Elk and Antelope fields in Papua New Guinea.
Can IOC Rebound After The Recent Slump and Investors Can Make Money? Find Out Here
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)